ProstACT phase 3 trial started recruiting in the US
ProstACT Global Phase 3 trial (NCT04876651) for TLX591, a PSMA-targeted radioligand therapy, globally in 2023, with a recent U.S. rollout announced on February 25, 2025, starting in Miami at Biogenix Molecular Research Center.
Unlike Pluvicto’s small-molecule approach, TLX591 uses an antibody (rosopatamab
ProstACT Global Phase 3 trial (NCT04876651) for TLX591, a PSMA-targeted radioligand therapy, globally in 2023, with a recent U.S. rollout announced on February 25, 2025, starting in Miami at Biogenix Molecular Research Center.
Unlike Pluvicto’s small-molecule approach, TLX591 uses an antibody (rosopatamab